

DAFTAR PUSTAKA

- ADA, 2023a. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. *Diabetes Care* 47, S20–S42. <https://doi.org/10.2337/dc24-S002>
- ADA, 2023b. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024. *Diabetes Care* 47, S111–S125. <https://doi.org/10.2337/dc24-S006>
- ADA, 2022a. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. *Diabetes Care* 46, S19–S40. <https://doi.org/10.2337/dc23-S002>
- ADA, 2022b. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023. *Diabetes Care* 46, S140–S157. <https://doi.org/10.2337/dc23-S009>
- ADA, 2016. Standards of Medical Care in Diabetes-2016: Summary of Revisions. *Diabetes Care* 39 Suppl 1, S4-5. <https://doi.org/10.2337/dc16-S003>
- ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L., Mancia, G., Mogensen, C.E., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bompoint, S., de Galan, B.E., Joshi, R., Travert, F., 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N. Engl. J. Med.* 358, 2560–2572. <https://doi.org/10.1056/NEJMoa0802987>
- Aldafas, R., Vinogradova, Y., Crabtree, T.S.J., Gordon, J., Idris, I., 2026. The long-term impact of early HbA1c control on nephropathy, neuropathy, and retinopathy in type 2 diabetes: Findings from a large UK observational study. *J. Diabetes Complications* 40, 109292. <https://doi.org/10.1016/j.jdiacomp.2026.109292>
- Aldhous, M.C., Reynolds, R.M., Campbell, A., Linksted, P., Lindsay, R.S., Smith, B.H., Seckl, J.R., Porteous, D.J., Norman, J.E., Scotland, G., 2015. Sex-Differences in the Metabolic Health of Offspring of Parents with Diabetes: A Record-Linkage Study. *PLOS ONE* 10, e0134883. <https://doi.org/10.1371/journal.pone.0134883>
- Alhassani, R.Y., Bagadood, R.M., Balubaid, R.N., Barno, H.I., Alahmadi, M.O., Ayoub, N.A., 2021. Drug Therapies Affecting Renal Function: An Overview. *Cureus* 13, e19924. <https://doi.org/10.7759/cureus.19924>
- Amir, N., Rusman, R., Amri, ayu wandira A.B., 2025. Pengaruh Lama Penggunaan Obat Anti Diabetik Oral Terhadap Fungsi Ginjal Pasien di Fasilitas Kesehatan Kecamatan Biringkanaya Kota Makassar. *J. Novem Med. Farm.* 4, 50–57. <https://doi.org/10.59638/junomefar.v4i3.1873>
- Antza, C., Stabouli, S., Kotsis, V., 2018. Gut microbiota in kidney disease and hypertension. *Pharmacol. Res.* 130, 198–203. <https://doi.org/10.1016/j.phrs.2018.02.028>
- Baba, M., Shimbo, T., Horio, M., Ando, M., Yasuda, Y., Komatsu, Y., Masuda, K., Matsuo, S., Maruyama, S., 2015. Longitudinal Study of the Decline in Renal

- Function in Healthy Subjects. *PLoS ONE* 10, e0129036.
<https://doi.org/10.1371/journal.pone.0129036>
- Belhatem, N., Mohammedi, K., Rouzet, F., Matallah, N., Baloshi, A.A., Travert, F., Velho, G., Roussel, R., Guludec, D.L., Marre, M., Hansel, B., 2015. Impact of morbid obesity on the kidney function of patients with type 2 diabetes. *Diabetes Res. Clin. Pract.* 108, 143–149.
<https://doi.org/10.1016/j.diabres.2015.01.028>
- Bennett, W.L., Maruthur, N.M., Singh, S., Segal, J.B., Wilson, L.M., Chatterjee, R., Marinopoulos, S.S., Puhon, M.A., Ranasinghe, P., Block, L., Nicholson, W.K., Hutfless, S., Bass, E.B., Bolen, S., 2011. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Ann. Intern. Med.* 154, 602–613.
<https://doi.org/10.7326/0003-4819-154-9-201105030-00336>
- Boudoulas, K.D., Triposkiadis, F., Parissis, J., Butler, J., Boudoulas, H., 2017. The Cardio-Renal Interrelationship. *Prog. Cardiovasc. Dis.* 59, 636–648.
<https://doi.org/10.1016/j.pcad.2016.12.003>
- Cahn, A., Melzer-Cohen, C., Pollack, R., Chodick, G., Shalev, V., 2019. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis. *Diabetes Obes. Metab.* 21, 340–348.
<https://doi.org/10.1111/dom.13532>
- Candraningrat, I.D.A.A.D., Handani, D.A.S., Putri, N.P.V.G., Buana, K.D.M., 2025. Clinical Outcomes of Antihypertensive Therapy in Chronic Kidney Disease: A Literature Review. *J. Syifa Sci. Clin. Res.* 7, 299–311.
<https://doi.org/10.37311/jsscr.v7i3.34331>
- Cao, C., Hu, H., Zheng, X., Zhang, X., Wang, Y., He, Y., 2022. Association between central obesity and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. *Sci. Rep.* 12, 13445. <https://doi.org/10.1038/s41598-022-17837-1>
- CDC, 2026. National Diabetes Statistics Report [WWW Document]. *Diabetes*. URL <https://www.cdc.gov/diabetes/php/data-research/index.html> (accessed 5.28.26).
- Chang, P.-Y., Chien, L.-N., Lin, Y.-F., Chiou, H.-Y., Chiu, W.-T., 2015. Nonadherence of Oral Antihyperglycemic Medication Will Increase Risk of End-Stage Renal Disease. *Medicine (Baltimore)* 94, e2051.
<https://doi.org/10.1097/MD.0000000000002051>
- Chang, Y.-H., Hwu, D.-W., Chang, D.-M., An, L.-W., Hsieh, C.-H., Lee, Y.-J., 2017. Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus. *Acta Diabetol.* 54, 561–568. <https://doi.org/10.1007/s00592-017-0983-0>
- Chen, X., Wu, R., Kong, Y., Yang, Y., Gao, Y., Sun, D., Liu, Q., Dai, D., Lu, Z., Wang, N., Ge, S., Wang, F., 2017. Tanshinone II A attenuates renal damage in STZ-induced diabetic rats via inhibiting oxidative stress and inflammation. *Oncotarget* 8, 31915–31922.
<https://doi.org/10.18632/oncotarget.16651>
- Chen, Y.-H., Tarng, D.-C., Chen, H.-S., 2016. Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled

- Study. PloS One 11, e0165750.
<https://doi.org/10.1371/journal.pone.0165750>
- Cherney, D.Z.I., Bakris, G.L., 2018. Novel therapies for diabetic kidney disease. *Kidney Int. Suppl.* 8, 18–25. <https://doi.org/10.1016/j.kisu.2017.10.005>
- Cooper, M.E., Perkovic, V., McGill, J.B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., Eynatten, M. von, 2015. Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. *Am. J. Kidney Dis.* 66, 441–449. <https://doi.org/10.1053/j.ajkd.2015.03.024>
- DCCT, 1993. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *N. Engl. J. Med.* 329, 977–986. <https://doi.org/10.1056/NEJM199309303291401>
- De Bhailis, Á.M., Kalra, P.A., 2022. Hypertension and the kidneys. *Br. J. Hosp. Med. Lond. Engl.* 2005 83, 1–11. <https://doi.org/10.12968/hmed.2021.0440>
- De Broe, M.E., Kajbaf, F., Lalau, J.-D., 2018. Renoprotective Effects of Metformin. *Nephron* 138, 261–274. <https://doi.org/10.1159/000481951>
- de Zeeuw D, dkk, H.-, 2015. Different statins may have different renal effects in diabetic patients with proteinuria - PACE-CME [WWW Document]. URL <https://pace-cme.org/news/different-statins-may-have-different-renal-effects-in-diabetic-patients-with-proteinuria/2454266/> (accessed 5.29.26).
- Deferrari, G., Cipriani, A., La Porta, E., 2021. Renal dysfunction in cardiovascular diseases and its consequences. *J. Nephrol.* 34, 137–153. <https://doi.org/10.1007/s40620-020-00842-w>
- Denic, A., Alexander, M.P., Kaushik, V., Lerman, L.O., Lieske, J.C., Stegall, M.D., Larson, J.J., Kremers, W.K., Vrtiska, T.J., Chakkera, H.A., Poggio, E.D., Rule, A.D., 2016. Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. *Am. J. Kidney Dis. Off. J. Natl. Kidney Found.* 68, 58–67. <https://doi.org/10.1053/j.ajkd.2015.12.029>
- Denic, A., Lieske, J.C., Chakkera, H.A., Poggio, E.D., Alexander, M.P., Singh, P., Kremers, W.K., Lerman, L.O., Rule, A.D., 2017a. The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging. *J. Am. Soc. Nephrol. JASN* 28, 313–320. <https://doi.org/10.1681/ASN.2016020154>
- Dronavalli, S., Duka, I., Bakris, G.L., 2008. The pathogenesis of diabetic nephropathy. *Nat. Clin. Pract. Endocrinol. Metab.* 4, 444–452. <https://doi.org/10.1038/ncpendmet0894>
- Estoppey, P., Clair, C., Auderset, D., Puder, J.J., 2023. Sex Differences in Type 2 Diabetes. *Cardiovasc. Med.* 26, 96. <https://doi.org/10.4414/cvm.2023.02273>
- Fioretto, P., Zambon, A., Rossato, M., Busetto, L., Vettor, R., 2016. SGLT2 Inhibitors and the Diabetic Kidney. *Diabetes Care* 39 Suppl 2, S165–171. <https://doi.org/10.2337/dcS15-3006>

- Fujita, Y., Inagaki, N., 2017. Metformin: New Preparations and Nonglycemic Benefits. *Curr. Diab. Rep.* 17, 5. <https://doi.org/10.1007/s11892-017-0829-8>
- Gerdes, C., Müller, N., Wolf, G., Busch, M., 2023. Nephroprotective Properties of Antidiabetic Drugs. *J. Clin. Med.* 12, 3377. <https://doi.org/10.3390/jcm12103377>
- Goldberg, I., Krause, I., 2016. The Role of Gender in Chronic Kidney Disease.
- Goyal, R., Singhal, M., Jialal, I., 2025. Type 2 Diabetes, in: StatPearls. StatPearls Publishing, Treasure Island (FL).
- Gupta, A., Nagaraju, S.P., Bhojaraja, M.V., Swaminathan, S.M., Mohan, P.B., 2023. Hypertension in Chronic Kidney Disease: An Update on Diagnosis and Management. *South. Med. J.* 116, 237–244. <https://doi.org/10.14423/SMJ.0000000000001516>
- Hahr, A.J., Molitch, M.E., 2015. Management of diabetes mellitus in patients with chronic kidney disease. *Clin. Diabetes Endocrinol.* 1, 2. <https://doi.org/10.1186/s40842-015-0001-9>
- Han, E., Kim, G., Lee, J.-Y., Lee, Y., Kim, B.S., Lee, B.-W., Cha, B.-S., Kang, E.S., 2017. Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes. *Endocrinol. Metab.* 32, 274–280. <https://doi.org/10.3803/EnM.2017.32.2.274>
- Heerspink, H.J.L., Cherney, David, Postmus, D., 2022. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. *Kidney Int.* 101, 174–184. <https://doi.org/10.1016/j.kint.2021.09.005>
- Heerspink, H.J.L., Desai, M., Jardine, M., Balis, D., Meininger, G., Perkovic, V., 2017. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. *J. Am. Soc. Nephrol.* 28, 368. <https://doi.org/10.1681/ASN.2016030278>
- Heerspink, H.J.L., Stefánsson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F.-F., Mann, J.F.E., McMurray, J.J.V., Lindberg, M., Rossing, P., Sjöström, C.D., Toto, R.D., Langkilde, A.-M., Wheeler, D.C., 2020. Dapagliflozin in Patients with Chronic Kidney Disease. *N. Engl. J. Med.* 383, 1436–1446. <https://doi.org/10.1056/NEJMoa2024816>
- Helal, I., Fick-Brosnahan, G.M., Reed-Gitomer, B., Schrier, R.W., 2012. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. *Nat. Rev. Nephrol.* 8, 293–300. <https://doi.org/10.1038/nrneph.2012.19>
- H.-J. Tsai., dkk, 2015. Use of non-steroidal anti-inflammatory drugs and... : Diabetic Medicine [WWW Document]. Ovid. <https://doi.org/10.1111/dme.12610>
- Ho, C.-C., Yang, Y.-S., Huang, C.-N., Lo, S.-C., Wang, Y.-H., Kornelius, E., 2022. The efficacy of pioglitazone for renal protection in diabetic kidney disease. *PLOS ONE* 17, e0264129. <https://doi.org/10.1371/journal.pone.0264129>

- Hommos, M.S., Glassock, R.J., Rule, A.D., 2017. Structural and Functional Changes in Human Kidneys with Healthy Aging. *J. Am. Soc. Nephrol.* JASN 28, 2838–2844. <https://doi.org/10.1681/ASN.2017040421>
- Hou, Q., Huang, G., Kan, S., Yang, R., Ma, Z., Zhu, X., Zeng, C., Jiang, S., Liu, Z., 2026. Acarbose ameliorates podocyte injury and glomerular lesions in diabetic nephropathy through USP46 activation. *Sci. Transl. Med.* 18, eads4585. <https://doi.org/10.1126/scitranslmed.ads4585>
- Hsu, W.-H., Hsiao, P.-J., Lin, P.-C., Chen, S.-C., Lee, M.-Y., Shin, S.-J., 2018. Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. *Oncotarget* 9, 5416–5423. <https://doi.org/10.18632/oncotarget.23387>
- Hung, A.M., Roumie, C.L., Greevy, R.A., Liu, X., Grijalva, C.G., Murff, H.J., Ikizler, T.A., Griffin, M.R., 2012. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. *Kidney Int.* 81, 698–706. <https://doi.org/10.1038/ki.2011.444>
- IDF, 2025. Diabetes Atlas 11th Edition. Diabetes Atlas 11th Ed. URL <https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/> (accessed 6.4.25).
- Imai, E., Horio, M., Yamagata, K., Iseki, K., Hara, S., Ura, N., Kiyohara, Y., Makino, H., Hishida, A., Matsuo, S., 2008. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. *Hypertens. Res. Off. J. Jpn. Soc. Hypertens.* 31, 433–441. <https://doi.org/10.1291/hypres.31.433>
- Jamal Shahwan, M., Hassan, N.A. galil, Shaheen, R.A., 2019. Assessment of kidney function and associated risk factors among type 2 diabetic patients. *Diabetes Metab. Syndr. Clin. Res. Rev.* 13, 2661–2665. <https://doi.org/10.1016/j.dsx.2019.07.025>
- Jc, A.F., M, M., N, B., H, G., Gt, G., Cm, S., Kd, K., Bj, G., 2013. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. *Diabetes Care* 36. <https://doi.org/10.2337/dc12-1365>
- Kadowaki, T., Nangaku, M., Hantel, S., Okamura, T., von Eynatten, M., Wanner, C., Koitka-Weber, A., 2019. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial. *J. Diabetes Investig.* 10, 760–770. <https://doi.org/10.1111/jdi.12971>
- Kanaley, J.A., Colberg, S.R., Corcoran, M.H., Malin, S.K., Rodriguez, N.R., Crespo, C.J., Kirwan, J.P., Zierath, J.R., 2022. Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. *Med. Sci. Sports Exerc.* 54, 353–368. <https://doi.org/10.1249/MSS.0000000000002800>
- Kanasaki, K., 2018. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. *Clin. Sci.* 132, 489–507. <https://doi.org/10.1042/CS20180031>
- Kasiske, B.L., Kalil, R.S., Ma, J.Z., Liao, M., Keane, W.F., 1993. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-

- regression analysis. *Ann. Intern. Med.* 118, 129–138. <https://doi.org/10.7326/0003-4819-118-2-199301150-00009>
- Kautzky-Willer, A., Leutner, M., Harreiter, J., 2023. Sex differences in type 2 diabetes. *Diabetologia* 66, 986–1002. <https://doi.org/10.1007/s00125-023-05891-x>
- Kemenkes RI, 2024. Laporan Tematik Survey Kesehatan Indonesia Tahun 2023. Badan Kebijakan. Pembang. Kesehat. BKPK Kemenkes. URL <https://www.badankebijakan.kemkes.go.id/laporan-tematik-ski/> (accessed 6.5.25).
- Kim, J.-J., Wilbon, S.S., Fornoni, A., 2021. Podocyte Lipotoxicity in CKD. *Kidney* 360 2, 755–762. <https://doi.org/10.34067/KID.0006152020>
- Kim, Y.-G., Byun, J., Yoon, D., Jeon, J.Y., Han, S.J., Kim, D.J., Lee, K.-W., Park, R.W., Kim, H.J., 2016. Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study. *J. Diabetes Res.* 2016, 1423191. <https://doi.org/10.1155/2016/1423191>
- Kotsis, V., Stabouli, S., Papakatsika, S., Rizos, Z., Parati, G., 2010. Mechanisms of obesity-induced hypertension. *Hypertens. Res. Off. J. Jpn. Soc. Hypertens.* 33, 386–393. <https://doi.org/10.1038/hr.2010.9>
- Kuwatsuru, Y., Hirano, T., Wakabayashi, R., Ishisaki, J.Y., Sokooshi, H., Kuwatsuru, R., 2023. Changes in renal function over time in outpatients with eGFR ≥ 30 mL/min/1.73 m²: implication for timing of renal function testing before contrast-enhanced CT imaging. *Jpn. J. Radiol.* 41, 994–1006. <https://doi.org/10.1007/s11604-023-01425-y>
- Lachin, J.M., Viberti, G., Zinman, B., Haffner, S.M., Aftring, R.P., Paul, G., Kravitz, B.G., Herman, W.H., Holman, R.R., Kahn, S.E., ADOPT Study Group, 2011. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. *Clin. J. Am. Soc. Nephrol. CJASN* 6, 1032–1040. <https://doi.org/10.2215/CJN.09291010>
- Laiteerapong, N., Huang, E.S., 2018. Diabetes in Older Adults, in: Cowie, C.C., Casagrande, S.S., Menke, A., Cissell, M.A., Eberhardt, M.S., Meigs, J.B., Gregg, E.W., Knowler, W.C., Barrett-Connor, E., Becker, D.J., Brancati, F.L., Boyko, E.J., Herman, W.H., Howard, B.V., Narayan, K.M.V., Rewers, M., Fradkin, J.E. (Eds.), *Diabetes in America. National Institute of Diabetes and Digestive and Kidney Diseases (US), Bethesda (MD)*.
- Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., 2013. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. *Diabetes Obes. Metab.* 15, 853–862. <https://doi.org/10.1111/dom.12127>
- Lee, Y. -h., Lee, C.J., Lee, H.S., Choe, E.Y., Lee, B.-W., Ahn, C.W., Cha, B.-S., Lee, H.C., Balkau, B., Kang, E.S., 2015. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. *Diabetes Metab.* 41, 208–215. <https://doi.org/10.1016/j.diabet.2015.01.004>
- Lee, S., Lee, K.H., Song, M., Lee, D., 2011. Building the process-drug–side effect network to discover the relationship between biological Processes and side

- effects. *BMC Bioinformatics* 12, S2. <https://doi.org/10.1186/1471-2105-12-S2-S2>
- Lin, Y.-C., Lai, T.-S., Lin, S.-L., Chen, Y.-M., Chu, T.-S., Tu, Y.-K., 2021. The impact of baseline glomerular filtration rate on subsequent changes of glomerular filtration rate in patients with chronic kidney disease. *Sci. Rep.* 11, 7894. <https://doi.org/10.1038/s41598-021-86955-z>
- Liu, J., Ji, H., Zheng, W., Wu, X., Zhu, J.J., Arnold, A.P., Sandberg, K., 2010. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17 β -oestradiol-dependent and sex chromosome-independent. *Biol. Sex Differ.* 1, 6. <https://doi.org/10.1186/2042-6410-1-6>
- Lovshin, J.A., Rajasekaran, H., Lytvyn, Y., Lovblom, L.E., Khan, S., Alemu, R., Locke, A., Lai, V., He, H., Hittle, L., Wang, W., Drucker, D.J., Cherney, D.Z.I., 2017. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 α 1-67 in Patients With Type 2 Diabetes. *Diabetes Care* 40, 1073–1081. <https://doi.org/10.2337/dc17-0061>
- Lv, W., Wang, X., Xu, Q., Lu, W., 2020. Mechanisms and Characteristics of Sulfonylureas and Glinides. *Curr. Top. Med. Chem.* 20, 37–56. <https://doi.org/10.2174/1568026620666191224141617>
- Lydia, A., 2021. Minum Obat Jangka Panjang Tak Sebabkan Penyakit Ginjal, Begini Penjelasan Ahli [WWW Document]. *KOMPAS.com*. URL <https://www.kompas.com/sains/read/2021/03/10/173000223/minum-obat-jangka-panjang-tak-sebabkan-penyakit-ginjal-begini-penjelasan> (accessed 6.11.25).
- Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., Fu, S.-B., 2022. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. *Cardiovasc. Diabetol.* 21, 74. <https://doi.org/10.1186/s12933-022-01516-6>
- Machado-Duque, M.E., Gaviria-Mendoza, A., Valladales-Restrepo, L.F., Franco, J.S., de Rosario Forero, M., Vizcaya, D., Machado-Alba, J.E., 2023. Treatment patterns of antidiabetic and kidney protective therapies among patients with type 2 diabetes mellitus and chronic kidney disease in Colombia. The KDICO descriptive study. *Diabetol. Metab. Syndr.* 15, 150. <https://doi.org/10.1186/s13098-023-01126-6>
- MacIsaac, R.J., Jerums, G., Ekinci, E.I., 2017. Effects of glycaemic management on diabetic kidney disease. *World J. Diabetes* 8, 172–186. <https://doi.org/10.4239/wjd.v8.i5.172>
- Mahaffey, K.W., Jardine, M.J., Bompont, S., Cannon, C.P., Neal, B., Heerspink, H.J.L., Charytan, D.M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Capuano, G., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Sun, T., Wheeler, D.C., Yavin, Y., Zhang, H., Zinman, B., Rosenthal, N., Brenner, B.M., Perkovic, V., 2019. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. *Circulation* 140, 739–750. <https://doi.org/10.1161/CIRCULATIONAHA.119.042007>

- Marbun, R.A., Wahyuni, S., Hidayah, A., 2024. Evaluation Of Metformin Use in Type 2 Diabetes Mellitus Patients X Clinic Sei Karang. *J. KESMAS DAN GIZI JKG* 6, 277–280. <https://doi.org/10.35451/jkg.v6i2.2037>
- Margonato, D., Galati, G., Mazzetti, S., Cannistraci, R., Perseghin, G., Margonato, A., Mortara, A., 2021. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. *Heart Fail. Rev.* 26, 337–345. <https://doi.org/10.1007/s10741-020-10024-2>
- Mariano, F., Pozzato, M., Inguaggiato, P., Guarena, C., Turello, E., Manes, M., David, P., Berutti, S., Consiglio, V., Amore, A., Campo, A., Marino, A., Berto, M., Carpani, P., Calabrese, G., Gherzi, M., Stramignoni, E., Martina, G., Serra, A., Comune, L., Roscini, E., Marciello, A., Todini, V., Vio, P., Filiberti, O., Boero, R., Cantaluppi, V., 2017. Metformin-Associated Lactic Acidosis Undergoing Renal Replacement Therapy in Intensive Care Units: A Five-Million Population-Based Study in the North-West of Italy. *Blood Purif.* 44, 198–205. <https://doi.org/10.1159/000471917>
- Masica, A.L., Ewen, E., Daoud, Y.A., Cheng, D., Franceschini, N., Kudryakov, R.E., Bowen, J.R., Brouwer, E.S., Wallace, D., Fleming, N.S., West, S.L., 2013. Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease. <https://doi.org/10.1002/pds.3413>
- Masoumeh Ghoreishi, S., Amiri, M., Shabestani Monfared, A., Hamidi, F., Najafzadehvarzi, H., 2022. Therapeutic effect of antihypertensive drug on diabetic nephropathy: Functional and structural kidney investigation. *Saudi J. Biol. Sci.* 29, 103353. <https://doi.org/10.1016/j.sjbs.2022.103353>
- Mennuni, S., Rubattu, S., Pierelli, G., Tocci, G., Fofi, C., Volpe, M., 2014. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. *J. Hum. Hypertens.* 28, 74–79. <https://doi.org/10.1038/jhh.2013.55>
- Mikov, M., Pavlović, N., Stanimirov, B., Đanić, M., Goločorbin-Kon, S., Stankov, K., Al-Salami, H., 2020. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. *Eur. J. Drug Metab. Pharmacokinet.* 45, 1–14. <https://doi.org/10.1007/s13318-019-00570-y>
- Mitrofanova, A., Merscher, S., Fornoni, A., 2023. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. *Nat. Rev. Nephrol.* 19, 629–645. <https://doi.org/10.1038/s41581-023-00741-w>
- Mizukami, H., Kudoh, K., 2022. Diversity of pathophysiology in type 2 diabetes shown by islet pathology. *J. Diabetes Investig.* 13, 6–13. <https://doi.org/10.1111/jdi.13679>
- Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., Franczyk, B., 2025a. Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. *Int. J. Mol. Sci.* 26, 1094. <https://doi.org/10.3390/ijms26031094>
- Monami, M., Candido, R., Pintaudi, B., Targher, G., Mannucci, E., of the SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes,

2021. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Nutr. Metab. Cardiovasc. Dis. NMCD* 31, 2539–2546. <https://doi.org/10.1016/j.numecd.2021.05.010>
- Moorhead, J.F., Chan, M.K., El-Nahas, M., Varghese, Z., 1982. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. *Lancet Lond. Engl.* 2, 1309–1311. [https://doi.org/10.1016/s0140-6736\(82\)91513-6](https://doi.org/10.1016/s0140-6736(82)91513-6)
- Morales, A.I., Detaille, D., Prieto, M., Puente, A., Briones, E., Arévalo, M., Lerverve, X., López-Novoa, J.M., El-Mir, M.-Y., 2010. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. *Kidney Int.* 77, 861–869. <https://doi.org/10.1038/ki.2010.11>
- Naidoo, S., Meyers, A.M., 2015. Drugs and the kidney. *S. Afr. Med. J.* 105, 332–337.
- O’Hare, A.M., Choi, A.I., Bertenthal, D., Bacchetti, P., Garg, A.X., Kaufman, J.S., Walter, L.C., Mehta, K.M., Steinman, M.A., Allon, M., McClellan, W.M., Landefeld, C.S., 2007. Age affects outcomes in chronic kidney disease. *J. Am. Soc. Nephrol. JASN* 18, 2758–2765. <https://doi.org/10.1681/ASN.2007040422>
- Ong, K.L., Stafford, L.K., McLaughlin, S.A., Boyko, E.J., 2023. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet* 402, 203–234. [https://doi.org/10.1016/S0140-6736\(23\)01301-6](https://doi.org/10.1016/S0140-6736(23)01301-6)
- Pamungkas, P.M., Ginaris, R.P., Nurrahman, A., 2025. Evaluation of the Use of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients at the Outpatient Installation of Azizah Metro Hospital. *PHARMADEMICA J. Kefarmasian Dan Gizi* 5, 116–122. <https://doi.org/10.54445/pharmademica.v5i1.90>
- Pan, Q., Xu, Y., Yang, N., Gao, X., Liu, J., Yang, W., Wang, G., 2016. Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial. *Medicine (Baltimore)* 95, e3247. <https://doi.org/10.1097/MD.00000000000003247>
- Pantis, C., Vesa, C.M., Ghitea, T.C., Trifan, D.F., Brata, R.D., Pop, N.O., Moisi, M.I., 2026. Diabetes Duration Is Associated with Declining Kidney Function: eGFR and CKD Burden Across Duration. *J. Clin. Med.* 15, 2235. <https://doi.org/10.3390/jcm15062235>
- Park, M., Shlipak, M.G., Katz, R., Agarwal, S., Ix, J.H., Hsu, C.-Y., Peralta, C.A., 2012. Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of atherosclerosis. *Clin. J. Am. Soc. Nephrol. CJASN* 7, 1137–1144. <https://doi.org/10.2215/CJN.01230212>
- Park, Y.J., Kim, J.-M., 2018. Klotho and Postmenopausal Hormone Replacement Therapy in Women with Chronic Kidney Disease. *J. Menopausal Med.* 24, 75–80. <https://doi.org/10.6118/jmm.2018.24.2.75>

- Patel, B., Patel, C., Panchal, D., Patel, S., 2025. A retrospective evaluation of the trend of prevalence of type 2 diabetes mellitus in different age groups in a tertiary care hospital. <https://doi.org/10.18231/j.pjms.2021.028>
- Perazella, M.A., 2018. Pharmacology behind Common Drug Nephrotoxicities. *Clin. J. Am. Soc. Nephrol. CJASN* 13, 1897–1908. <https://doi.org/10.2215/CJN.00150118>
- PERKENI, 2021. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di INDONESIA - 2021.
- Perkovic, V., De Zeeuw, D., Mahaffey, K.W., Fulcher, G., Erondy, N., Shaw, W., Barrett, T.D., Weidner-Wells, M., Deng, H., Matthews, D.R., Neal, B., 2018. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol.* 6, 691–704. [https://doi.org/10.1016/S2213-8587\(18\)30141-4](https://doi.org/10.1016/S2213-8587(18)30141-4)
- Perkovic, V., Heerspink, H.L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M.E., Hamet, P., Marre, M., Mogensen, C.E., Poulter, N., Mancia, G., Cass, A., Patel, A., Zoungas, S., 2013. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. *Kidney Int.* 83. <https://doi.org/10.1038/ki.2012.401>
- Pourshabanan, P., Momeni, A., Mahmoudnia, L., Kheiri, S., 2019. Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy. *Diabetes Metab. Syndr. Clin. Res. Rev.* 13, 132–136. <https://doi.org/10.1016/j.dsx.2018.04.013>
- Prischl, F.C., Wanner, C., 2018a. Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes—A Proposed MARE Definition. *Kidney Int. Rep.* 3, 1030–1038. <https://doi.org/10.1016/j.ekir.2018.04.008>
- Rajapakse, N.W., Head, G.A., Kaye, D.M., 2016. Say NO to Obesity-Related Hypertension: Role of the L-Arginine-Nitric Oxide Pathway. *Hypertens. Dallas Tex* 1979 67, 813–819. <https://doi.org/10.1161/HYPERTENSIONAHA.116.06778>
- Reckelhoff, J.F., Samson, W.K., 2015. Sex and gender differences in cardiovascular, renal and metabolic diseases. *Am. J. Physiol. - Regul. Integr. Comp. Physiol.* 309, R1057–R1059. <https://doi.org/10.1152/ajpregu.00417.2015>
- Redon, J., Lurbe, E., 2015. The kidney in obesity. *Curr. Hypertens. Rep.* 17, 555. <https://doi.org/10.1007/s11906-015-0555-z>
- Rena, G., Hardie, D.G., Pearson, E.R., 2017. The mechanisms of action of metformin. *Diabetologia* 60, 1577–1585. <https://doi.org/10.1007/s00125-017-4342-z>
- Rosenstock, J., Perkovic, V., Johansen, O.E., Cooper, M.E., Kahn, S.E., Marx, N., Alexander, J.H., Pencina, M., Toto, R.D., Wanner, C., Zinman, B., Woerle, H.J., Baanstra, D., Pfarr, E., Schnaidt, S., Meinicke, T., George, J.T., von Eynatten, M., McGuire, D.K., for the CARMELINA Investigators, 2019. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *JAMA* 321, 69–79. <https://doi.org/10.1001/jama.2018.18269>

- RSA, 2025. Paket Medical Check Up (MCU). Rumah Sakit Akad. UGM. URL <https://rsa.ugm.ac.id/layanan/paket-medical-check-up-mcu/> (accessed 6.11.25).
- Saleem, M., Ullah, S., Nawaz, M., Shah, G., Muhammad, B., Khan, M.I., Khan, M.A., Idrees, M., 2024. Prevalence and Associated Risk Factors of Metformin Use in the Treatment of Type-2 Diabetes Mellitus: Metformin Use in Type-2 Diabetes. *J. Health Rehabil. Res.* 4, 1–6. <https://doi.org/10.61919/jhrr.v4i3.1693>
- Sanchez, D., Lebrun, A., Somda, S., Lainas, P., Lamouri, K., Prevot, S., Njike-Nakseu, M., Tranchart, H., Gaillard, M., Zaidan, M., Balian, A., Dagher, I., Naveau, S., Perlemuter, G., Voican, C.S., 2022. Impact of sleeve gastrectomy on renal function in patients with morbid obesity: a 1-year prospective cohort study. *Langenbecks Arch. Surg.* 407, 3323–3332. <https://doi.org/10.1007/s00423-022-02647-w>
- Sarafidis, P., Ferro, C.J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., London, G.M., Massy, Z., Ruggenenti, P., Porrini, E., Wiecek, A., Zoccali, C., Mallamaci, F., Hornum, M., 2019. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc.* 34, 208–230. <https://doi.org/10.1093/ndt/gfy407>
- Schneider, C.A., Ferrannini, E., DeFronzo, R., Schernthaner, G., Yates, J., Erdmann, E., 2008. Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease. *J. Am. Soc. Nephrol.* 19, 182. <https://doi.org/10.1681/ASN.2007060678>
- Shurraw, S., Hemmelgarn, B., Lin, M., Majumdar, S.R., Klarenbach, S., Manns, B., Bello, A., James, M., Turin, T.C., Tonelli, M., Network, for the A.K.D., 2011. Association Between Glycemic Control and Adverse Outcomes in People With Diabetes Mellitus and Chronic Kidney Disease: A Population-Based Cohort Study. *Arch Intern Med* 21, 171.
- Sulaiman, M.K., 2019. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. *Diabetol. Metab. Syndr.* 11, 7. <https://doi.org/10.1186/s13098-019-0403-4>
- Sullivan, M.K., Lees, J.S., Rosales, B.M., Cutting, R., Wyld, M.L., Woodward, M., Webster, A.C., Mark, P.B., De La Mata, N., 2024. Sex and the Relationship Between Cardiometabolic Risk Factors and Estimated GFR Decline: A Population-Based Cohort Study. *Am. J. Kidney Dis.* 84, 731-741.e1. <https://doi.org/10.1053/j.ajkd.2024.05.007>
- Taylor, S.I., Yazdi, Z.S., Beitelshees, A.L., 2021. Pharmacological treatment of hyperglycemia in type 2 diabetes. *J. Clin. Invest.* 131, e142243, 142243. <https://doi.org/10.1172/JCI142243>
- The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., Mayne, K.J., Ng, S.Y.A., Sammons, E., Zhu, D., Hill, M., Stevens, W.,

- Wallendszus, K., Brenner, S., Cheung, A.K., Liu, Z.-H., Li, J., Hooi, L.S., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Maggioni, A.P., Pontremoli, R., Deo, R., Goto, S., Rossello, X., Tuttle, K.R., Steubl, D., Petrini, M., Massey, D., Eilbracht, J., Brueckmann, M., Landray, M.J., Baigent, C., Haynes, R., 2023. Empagliflozin in Patients with Chronic Kidney Disease. *N. Engl. J. Med.* 388, 117–127. <https://doi.org/10.1056/NEJMoa2204233>
- Toyama, T., Kitagawa, K., Oshima, M., Kitajima, S., Hara, A., Iwata, Y., Sakai, N., Shimizu, M., Hashiba, A., Furuichi, K., Wada, T., 2020. Age differences in the relationships between risk factors and loss of kidney function: a general population cohort study. *BMC Nephrol.* 21, 477. <https://doi.org/10.1186/s12882-020-02121-z>
- Tsai, C.-W., Ting, I.-W., Yeh, H.-C., Kuo, C.-C., 2017. Longitudinal change in estimated GFR among CKD patients: A 10-year follow-up study of an integrated kidney disease care program in Taiwan. *PLoS ONE* 12, e0173843. <https://doi.org/10.1371/journal.pone.0173843>
- Tsioufis, C., Kokkinos, P., Macmanus, C., Thomopoulos, C., Faselis, C., Doumas, M., Stefanadis, C., Papademetriou, V., 2010. Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. *J. Hypertens.* 28, 2299–2308. <https://doi.org/10.1097/HJH.0b013e32833d95fe>
- UKPDS, 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *The Lancet* 352, 837–853. [https://doi.org/10.1016/S0140-6736\(98\)07019-6](https://doi.org/10.1016/S0140-6736(98)07019-6)
- Vidt, D.G., Ridker, P.M., Monyak, J.T., Schreiber, M.J., Cressman, M.D., 2011. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). *Clin. Ther.* 33, 717–725. <https://doi.org/10.1016/j.clinthera.2011.05.004>
- Wang, X., Vrtiska, T.J., Avula, R.T., Walters, L.R., Chakker, H.A., Kremers, W.K., Lerman, L.O., Rule, A.D., 2014. Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney. *Kidney Int.* 85, 677–685. <https://doi.org/10.1038/ki.2013.359>
- WHO, 2024. Non communicable diseases [WWW Document]. URL <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases> (accessed 6.13.25).
- Wolf, G.B., Scherberich, J.E., Fischer, P., Schoeppe, W., 1989. Isolation and characterization of dipeptidyl aminopeptidase IV from human kidney cortex. *Clin. Chim. Acta Int. J. Clin. Chem.* 179, 61–71. [https://doi.org/10.1016/0009-8981\(89\)90023-5](https://doi.org/10.1016/0009-8981(89)90023-5)
- Xie, Y., Bowe, B., Li, T., Xian, H., Balasubramanian, S., Al-Aly, Z., 2016. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. *J. Am. Soc. Nephrol. JASN* 27, 3153–3163. <https://doi.org/10.1681/ASN.2015121377>

- Yamout, H., Perkovic, V., Davies, M., Woo, V., de Zeeuw, D., Mayer, C., Vijapurkar, U., Kline, I., Usiskin, K., Meininger, G., Bakris, G., 2014. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. *Am. J. Nephrol.* 40, 64–74. <https://doi.org/10.1159/000364909>
- Yen, C.-L., Wu, C.-Y., See, L.-C., Li, Y.-J., Tseng, M.-H., Peng, W.-S., Liu, J.-R., Chen, Y.-C., Yen, T.-H., Tian, Y.-C., Yang, C.-W., Anderson, G.F., Yang, H.-Y., 2020. Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study. *Diabetes Care* 43, e152–e153. <https://doi.org/10.2337/dc20-1584>
- Yi, Y., Kwon, E.-J., Yun, G., Park, S., Jeong, J.C., Na, K.Y., Chin, H.J., Yoo, S., Kim, Seok, Oh, T.J., Kim, Sejoong, Jung, C.H., Lee, H., 2024. Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study. *Sci. Rep.* 14, 2081. <https://doi.org/10.1038/s41598-024-52078-4>
- Zhang, Junlin, Wu, Y., Zhang, Jie, Zhang, R., Wang, Y., Liu, F., 2023. ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease. *Metabolism.* 139, 155377. <https://doi.org/10.1016/j.metabol.2022.155377>
- Zhao, L., Li, S., Gao, Y., 2021. Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. *Ren. Fail.* 43, 718–728. <https://doi.org/10.1080/0886022X.2021.1915799>
- Zheng, Y., Ley, S.H., Hu, F.B., 2018. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat. Rev. Endocrinol.* 14, 88–98. <https://doi.org/10.1038/nrendo.2017.151>